Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Quratis, Inc.
EyeGene R&D head talks to Scrip at CPhI Korea about the development of its COVID-19 vaccine candidate EG-COVID, potential challenges in clinical trials and positioning and the over-riding importance of validating a viable mRNA platform.
GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium.
Gennova Biopharma’s mRNA ambitions are taking wing as its HDT Bio-partnered self-amplifying vaccine moves to Phase II. Notably, the company will have to prove superiority to AstraZeneca/Serum Institute’s Covishield in what appears to be the first comparative study for a COVID-19 vaccine candidate in India, Scrip learns.
Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.
- Contract Manufacturing Organization
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.